Психічні та поведінкові розлади

Дата конвертації16.03.2018
Розмір5.37 Mb.
1   ...   70   71   72   73   74   75   76   77   ...   85

Список цитованої літератури

Abbott, P. J. (2009). A review of the community reinforcement approach in the treatment of opioid dependence. Journal of Psychoactive Drugs, 41(4), 379-385.

Abrahams, R. R., Kelly, S. A., Payne, S., Thiessen, P. N., Mackintosh, J., & Janssen, P. A. (2007). Rooming-in compared with standard care for newborns of mothers using methadone or heroin. Canadian Family Physician, 53(10), 1722-1730.

Adi, Y., Juarez-Garcia, A., Wang, D., Jowett, S., Frew, E., Day, E., . . . Burls, A. (2007). Oral naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: a systematic review and economic evaluation. Health Technology Assessment, 11(6), 1-85.

Ahmadi, J. (2002). A randomized, clinical trial of buprenorphine maintenance treatment for Iranian patients with opioid dependency. Addictive Disorders and their Treatment, 1(1), 25-27.

Ahmadi, J., & Ahmadi, M. (2003). Twelve-month maintenance treatment of heroin-dependent outpatients with buprenorphine. Journal of Substance Use, 8(1), 39-41.

Alterman, A. I., Rutherford, M. J., Cacciola, J. S., McKay, J. R., & Boardman, C. R. (1998). Prediction of 7 months methadone maintenance treatment response by four measures of antisociality. Drug and Alcohol Dependence, 49(3), 217-223.

Amass, L., Bickel, W. K., Crean, J. P., Blake, J., & Higgins, S. T. (1998). Alternate-day buprenorphine dosing is preferred to daily dosing by opioid-dependent humans. Psychopharmacology, 136(3), 217-225.

Amass, L., Bickel, W. K., Higgins, S. T., & Badger, G. J. (1994). Alternate-day dosing during buprenorphine treatment of opioid dependence. Life Sciences, 54(17), 1215-1228.

Amass, L., Bickel, W. K., Higgins, S. T., & Hughes, J. R. (1994). A preliminary investigation of outcome following gradual or rapid buprenorphine detoxification. Journal of Addictive Diseases, 13(3), 33-45.

Amass, L., Kamien, J. B., & Mikulich, S. K. (2000). Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet. Drug and Alcohol Dependence, 58(1-2), 143-152.

Amass, L., Kamien, J. B., & Mikulich, S. K. (2001). Thrice-weekly supervised dosing with the combination buprenorphine-naloxone tablet is preferred to daily supervised dosing by opioid-dependent humans. Drug and Alcohol Dependence, 61(2), 173-181.

Amass, L., Pukeleviciene, V., Subata, E., Almeida, A. R., Pieri, M. C., D'Egidio, P., . . . Strang, J. (2011). A prospective, randomized, multicenter acceptability and safety study of direct buprenorphine/naloxone induction in heroin-dependent individuals. Addiction, 107, 142-151.

Amato, L., Davoli, M., Minozzi, S., Ferroni, E., Ali, R., & Ferri, M. (2013). Methadone at tapered doses for the management of opioid withdrawal. Cochrane Database of Systematic Reviews(2). doi: 10.1002/14651858.CD003409.pub3.

Amato, L., Minozzi, S., Davoli, M., & Vecchi, S. (2011a). Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database of Systematic Reviews, 9, CD005031.

Amato, L., Minozzi, S., Davoli, M., & Vecchi, S. (2011b). Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database of Systematic Reviews(10). doi: 10.1002/14651858.CD004147.pub4

Anchersen, K., Clausen, T., Gossop, M., Hansteen, V., & Waal, H. (2009). Prevalence and clinical relevance of corrected QT interval prolongation during methadone and buprenorphine treatment: a mortality assessment study. Addiction, 104(6), 993-999.

Antela, A., Casado, J. L., Gonzalez, M. J., Perez, P., Perez-Elias, M. J., Montilla, P., & Buzon, L. (1997). Influence of a methadone maintenance programme on the improved outcome of a cohort of injecting drug users with advanced HIV disease. AIDS, 11(11), 1405-1406.

Baca, C. T., & Grant, K. J. (2005). Take-home naloxone to reduce heroin death. Addiction, 100(12), 1823-1831.

Baker, A., Gowing, L., Lee, N. K., & Proudfoot, H. (2004). Psychosocial interventions. In A. Baker, N. K. Lee & L. Jenner (Eds.), Models of intervention and care for psychostimulant users (pp. 63-84). Canberra: Commonwealth of Australia.

Bakstad, B., Sarfi, M., Welle-Strand, G. K., & Ravndal, E. (2009). Opioid maintenance treatment during pregnancy: Occurrence and severity of neonatal abstinence syndrome. European Addiction Research, 15(3), 128-134.

Ball, J. C., Lange, W. R., Myers, C. P., & Friedman, S. R. (1988). Reducing the risk of AIDS through methadone maintenance treatment. Journal of Health and Social Behavior, 29(3), 214-226.

Batki, S. L., Gruber, V. A., Bradley, J. M., Bradley, M., & Delucchi, K. (2002). A controlled trial of methadone treatment combined with directly observed isoniazid for tuberculosis prevention in injection drug users. Drug and Alcohol Dependence, 66(3), 283-293.

Bauer, C. R., Shankaran, S., Bada, H. S., Lester, B., Wright, L. L., Krause-Steinrauf, H., . . . Verter, J. (2002). The Maternal Lifestyle Study: Drug exposure during pregnancy and short-term maternal outcomes. American Journal of Obstetrics and Gynecology, 186(3), 487-495.

Bearn, J., Gossop, M., & Strang, J. (1999). Rapid opiate detoxification treatments. Drug and Alcohol Review, 18(1), 75-81.

Becker, A. B., Strain, E. C., Bigelow, G. E., Stitzer, M. L., & Johnson, R. E. (2001). Gradual dose taper following chronic buprenorphine. American Journal on Addictions, 10(2), 111-121.

Bell, J. (1998). Delivering effective methadone treatment. In J. Ward, R. P. Mattick & W. Hall (Eds.), Methadone Maintenance Treatment and Other Opioid Replacement Therapies (pp. 161-175). Amsterdam: Harwood Academic Publishers.

Bell, J., Chan, J., & Kuk, A. (1995). Investigating the influence of treatment philosophy on outcome of methadone maintenance. Addiction, 90(6), 823-830.

Bellack, A. S., & Gearon, J. S. (1998). Substance abuse treatment for people with schizophrenia. Addictive Behaviors, 23(6), 749-766.

Berghella, V., Lim, P. J., Hill, M. K., Cherpes, J., Chennat, J., & Kaltenbach, K. (2003). Maternal methadone dose and neonatal withdrawal. American Journal of Obstetrics and Gynecology, 189(2), 312-317.

Binder, T., & Vavrinková, B. (2008). Prospective randomised comparative study of the effect of buprenorphine, methadone and heroin on the course of pregnancy, birthweight of newborns, early postpartum adaptation and course of the neonatal abstinence syndrome (NAS) in women followed up in the outpatient department. Neuroendocrinology Letters, 29(1), 80-86.

Bisaga, A., Sullivan, M. A., Cheng, W. Y., Carpenter, K. M., Mariani, J. J., Levin, F. R., . . . Nunes, E. V. (2011). A placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependence. Drug and Alcohol Dependence, 119, e23-e29.

Bond, A. J., Reed, K. D., Beavan, P., & Strang, J. (2012). After the randomised injectable opiate treatment trial: Post-trial investigation of slow-release oral morphine as an alternative opiate maintenance medication. Drug and Alcohol Review, 31(4), 492-498.

Bowman, J., Wiggers, J., Colyvas, K., Wye, P., Walsh, R. A., & Bartlem, K. (2012). Smoking cessation among Australian methadone clients: Prevalence, characteristics and a need for action. Drug and Alcohol Review, 31(4), 507-513.

Boyd, J., Randell, T., Luurila, H., & Kuisma, M. (2003). Serious overdoses involving buprenorphine in Helsinki. Acta Anaesthesiologica Scandinavica, 47(8), 1031-1033.

Brahen, L. S., Henderson, R. K., Capone, T., & Kordal, N. (1984). Naltrexone treatment in a jail work-release program. Journal of Clinical Psychiatry, 45(9, Sec. 2), 49-52.

Bramness, J. G., Skurtveit, S., Morland, J., & Engeland, A. (2012). An increased risk of motor vehicle accidents after prescription of methadone. Addiction, 107, 967-972.

Brown, A. S., & Fleming, P. M. (1998). A naturalistic study of home detoxification from opiates using lofexidine. Journal of Psychopharmacology, 12(1), 93-96.

Brown, C. H., Bennett, M. E., Li, L., & Bellack, A. S. (2011). Predictors of initiation and engagement in substance abuse treatment among individuals with co-occurring serious mental illness and substance use disorders. Addictive Behaviors, 36(5), 439-447.

Brown, R. T., & Zueldorff, M. (2007). Opioid substitution with methadone and buprenorphine: Sexual dysfunction as a side effect of therapy. Heroin Addiction & Related Clinical Problems, 9(1), 35-44.

Bukten, A., Skurtveit, S., Gossop, M., Waal, H., Stangeland, P., Havnes, I., & Clausen, T. (2012). Engagement with opioid maintenance treatment and reductions in crime: a longitudinal national cohort study. Addiction, 107(2), 393-399.

Burns, L., Mattick, R. P., Lim, K., & Wallace, C. (2007). Methadone in pregnancy: treatment retention and neonatal outcomes. Addiction, 102(2), 264-270.

Burns, L., Randall, D., Hall, W. D., Law, M., Butler, T., Bell, J., & Degenhardt, L. (2009). Opioid agonist pharmacotherapy in New South Wales from 1985 to 2006: patient characteristics and patterns and predictors of treatment retention. Addiction, 104(8), 1363-1372.

Cacciola, J. S., & Rutherford, M. (1996). Personality disorders and treatment outcome in methadone maintenance patients. Journal of Nervous and Mental Disease, 184(4), 236-239.

Cami, J., Gilabert, M., San, L., & de la Torre, R. (1992). Hypercortisolism after opioid discontinuation in rapid detoxification of heroin addicts. British Journal of Addiction, 87(8), 1145-1151.

Carrieri, M. P., Amass, L., Lucas, G. M., Vlahov, D., Wodak, A., & Woody, G. E. (2006). Buprenorphine use: The international experience. Clinical Infectious Diseases, 43(Suppl 4), S197-S215.

Chiang, C. N., & Hawks, R. L. (2003). Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Drug and Alcohol Dependence, 70(Suppl), S39-S47.

Chou, R., Hartung, D., Rahman, B., Wasson, N., Cottrell, E. B., & Fu, R. (2013). Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: A systematic review. Annals of Internal Medicine, 158, 114-123.

Christo, G., & Franey, C. (1995). Drug users' spiritual beliefs, locus of control and the disease concept in relation to Narcotics Anonymous attendance and six-month outcomes. Drug and Alcohol Dependence, 38, 51-56.

Clark, N. C., Lintzeris, N., & Muhleisen, P. J. (2002). Severe opiate withdrawal in a heroin user precipitated by a massive buprenorphine dose. Medical Journal of Australia, 176(4), 166-167.

Cleary, B. J., Donnelly, J., Strawbridge, J., Gallagher, P. J., Fahey, T., Clarke, M., & Murphy, D. J. (2010). Methadone dose and neonatal abstinence syndrome - systematic review and meta-analysis. Addiction, 105(12), 2071-2084.

Cleary, B. J., Reynolds, K., Eogan, M., O'Connell, M. P., Fahey, T., Gallagher, P. J., . . . Murphy, D. J. (2013). Methadone dosing and prescribed medication use in a prospective cohort of opioid-dependent pregnant women. Addiction, 108, 762-770.

Cleaver, H., Unell, I., & Aldgate, J. (2011). Children's Needs - Parenting Capacity (2nd ed.). London, UK: TSO (The Stationery Office).

Comer, S. D., Collins, E. D., & Fischman, M. W. (2001). Buprenorphine sublingual tablets: effects on IV heroin self-administration by humans. Psychopharmacology, 154(1), 28-37.

Comer, S. D., Sullivan, M. A., Yu, E., Rothenberg, J. L., Kleber, H. D., Kampman, K., . . . O'Brien, C. P. (2006). Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Archives of General Psychiatry, 63(2), 210-218.

Conway, K. P., Compton, W., Stinson, F. S., & Grant, B. F. (2006). Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Journal of Clinical Psychiatry, 67(2), 247-257.

Cook, C. C. H. (1988). The Minnesota Model in the Management of Drug and Alcohol Dependency: miracle, method or myth? Part I. The Philosophy and the Programme. British Journal of Addiction, 83, 625-634.

Copeland, J., Gerber, S., & Swift, W. (2006). Evidence-based answers to cannabis questions: a review of the literature. Canberra: Australian National Council on Drugs.

Copello, A., Orford, J., Hodgson, R., Tober, G., & Barrett, C. (2002). Social behaviour and network therapy: Basic principles and early experiences. Addictive Behaviors, 27, 345-366.

Copello, A., Williamson, E., Orford, J., & Day, E. (2006). Implementing and evaluating Social Behaviour and Network Therapy in drug treatment practice in the UK: A feasibility study. Addictive Behaviors, 31, 802-810.

Cornish, R., Macleod, J., Strang, J., Vickerman, P., & Hickman, M. (2010). Risk of death during and after opiate substitution treatment in primary care: Prospective observational study in UK General Practice Research Database. BMJ, 341, c5475.

Corsenac, P., Lagarde, E., Gadegbeku, B., Delorme, B., Tricotel, A., Castot, A., . . . Orriols, L. (2012). Road traffic crashes and prescribed methadone and buprenorphine: A French registry-based case-control study. Drug and Alcohol Dependence, 123, 91-97.

Cousins, G., Teljeur, C., Motterlini, N., McCowan, C., Dimitrov, B. D., & Fahey, T. (2011). Risk of drug-related mortality during periods of transition in methadone maintenance treatment: A cohort study. Journal of Substance Abuse Treatment, 41, 252-260.

Coyle, M. G., Salisbury, A. L., Lester, B. M., Jones, H. E., Lin, H., Graf-Rohrmeister, K., & Fischer, G. (2012). Neonatal neurobehavior effects following buprenorphine versus methadone exposure. Addiction, 107(Suppl 1), 63-73.

Croop, R. S., Faulkner, E. B., & Labriola, D. F. (1997). The safety profile of naltrexone in the treatment of alcoholism. Archives of General Psychiatry, 54, 1130-1135.

Cropsey, K. L., Lane, P. S., Hale, G. J., Jackson, D. O., Clark, C. B., Ingersoll, K. S., . . . Stitzer, M. L. (2011). Results of a pilot randomized controlled trial of buprenorphine for opioid dependent women in the criminal justice system. Drug and Alcohol Dependence, 119, 172-178.

Cushman, P. (1974). Detoxification of rehabilitated methadone patients: frequency and predictors of long-term success. American Journal of Drug and Alcohol Abuse, 1(3), 393-408.

D'Ippoliti, D., Davoli, M., Perucci, C. A., Pasqualini, F., & Bargagli, A. M. (1998). Retention in treatment of heroin users in Italy: the role of treatment type and of methadone maintenance dosage. Drug and Alcohol Dependence, 52, 167-171.

Darke, S. (1998). Self-report among injecting drug users: a review. Drug and Alcohol Dependence, 51(3), 253-263.

Darke, S., Finlay-Jones, R., Kaye, S., & Blatt, T. (1996). Anti-social personality disorder and response to methadone maintenance treatment. Drug and Alcohol Review, 15, 271-276.

Darke, S., McDonald, S., Kaye, S., & Torok, M. (2012). Comparative patterns of cognitive performance amongst opioid maintenance patients, abstinent opioid users and non-opioid users. Drug and Alcohol Dependence, 126(3), 309-315.

Darke, S., Mills, K. L., Ross, J., & Teesson, M. (2011). Rates and correlates of mortality amongst heroin users: Findings from the Australian Treatment Outcome Study (ATOS), 2001-2009. Drug and Alcohol Dependence, 115(3), 190-195.

Darke, S., Ross, J., Mills, K. L., Williamson, A., Havard, A., & Teesson, M. (2007). Patterns of sustained heroin abstinence amongst long-term, dependent heroin users: 36 months findings from the Australian Treatment Outcome Study (ATOS). Addictive Behaviors, 32(9), 1897-1906.

Day, E. (2012). Commentary on Nosyk et al. (2012): Detoxification from methadone maintenance therapy: how important is the exact technique that is used? Addiction, 107, 1630-1631.

Day, E., Ison, J., & Strang, J. (2008). Inpatient versus other settings for detoxification for opioid dependence. Cochrane Database of Systematic Reviews(4). doi: 10.1002/14651858.CD004580.pub2

Dean, A. J., Bell, J., Christie, M. J., & Mattick, R. P. (2004). Depressive symptoms during buprenorphine vs. methadone maintenance: findings from a randomised, controlled trial in opioid dependence. European Psychiatry, 19(8), 510-513.

Dean, A. J., Saunders, J. B., Jones, R. T., Young, R. M., Connor, J. P., & Lawford, B. R. (2006). Does naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependence. Journal of Psychiatry and Neuroscience, 31(1), 38-45.

Degenhardt, L., Larance, B. K., Bell, J. R., Winstock, A. R., Lintzeris, N., Ali, R. L., . . . Mattick, R. P. (2009). Injection of medications used in opioid substitution treatment in Australia after the introduction of a mixed partial agonist–antagonist formulation. MJA, 191, 161-165.

Degenhardt, L., Randall, D., Hall, W., Law, M., Butler, T., & Burns, L. (2009). Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved. Drug and Alcohol Dependence, 105(1-2), 9-15.

Des Jarlais, D. C., Friedman, S. R., Woods, J., & Milliken, J. (1992). HIV infection among intravenous drug users: Epidemiology and emerging public health perspectives. In J. H. Lowinson, P. Ruiz, R. B. Millman & J. G. Langrod (Eds.), Substance Abuse: A Comprehensive Textbook (2nd ed., pp. 734-743). Baltimore: Williams & Wilkins.

DiClemente, C. C., Nidecker, M., & Bellack, A. S. (2008). Motivation and the stages of change among individuals with severe mental illness and substance abuse disorders. Journal of Substance Abuse Treatment, 34(1), 25-35.

Doran, C., Holmes, J., Ladewig, D., & Ling, W. (2005). Buprenorphine induction and stabilisation in the treatment of opiate dependence. Heroin Addiction & Related Clinical Problems, 7(1), 7-18.

Doris, J. L., Meguid, V., Thomas, M., Blatt, S., & Eckenrode, J. (2006). Prenatal cocaine exposure and child welfare outcomes. Child Maltreatment, 11(4), 326-337.

Drummond, D. C. (2001). Theories of drug craving, ancient and modern. Addiction, 96, 33-46.

Dunlop, A., Petroulias, D., Marope, D., Khoo, K., Kimber, J., Ritter, A., . . . Osborn, D. A. (2009). Pharmacotherapies and pregnancy. In R. P. Mattick, R. Ali & N. Lintzeris (Eds.), Pharmacotherapies for Opioid Dependence Treatment (pp. 282-329). London, UK: Informa Healthcare.

Dunn, C., Deroo, L., & Rivara, F. P. (2001). The use of brief interventions adapted from motivational interviewing across behavioral domains: a systematic review. Addiction, 96(12), 1725-1742.

Dyer, K. R. (2005). Methadone maintenance treatment and mood disturbances: Pharmacological and psychological implications. Heroin Addiction & Related Clinical Problems, 7(2), 5-10.

Dyer, K. R., & White, J. M. (1997). Patterns of symptom complaints in methadone maintenance patients. Addiction, 92(11), 1445-1455.

Eap, C. B., Buclin, T., & Baumann, P. (2002). Interindividual variability of the clinical pharmacokinetics of methadone. Clinical Pharmacokinetics, 41(14), 1153-1193.

Egli, N., Pina, M., Christensen, P. S., Aebi, M., & Killias, M. (2009). Effects of drug substitution programs on offending among drug-addicts. Campbell Systematic Reviews, 3.

Eissenberg, T., Greenwald, M. K., Johnson, R. E., Liebson, I. A., Bigelow, G. E., & Stitzer, M. L. (1996). Buprenorphine's physical dependence potential: antagonist-precipitated withdrawal in humans. Journal of Pharmacology and Experimental Therapeutics, 276(2), 449-459.

el-Guebaly, N. (2012). The meanings of recovery from addiction: evolution and promises. Journal of Addiction Medicine, 6(1), 1-9.

Elkader, A., & Sproule, B. (2005). Buprenorphine: Clinical pharmacokinetics in the treatment of opioid dependence. Clinical Pharmacokinetics, 44(7), 661-680.

Elkader, A. K., Brands, B., Selby, P., & Sproule, B. A. (2009). Methadone-nicotine interactions in methadone maintenance treatment patients. Journal of Clinical Psychopharmacology, 29(3), 231-238.

Faggiano, F., Vigna-Taglianti, F., Versino, E., & Lemma, P. (2003). Methadone maintenance at different dosages for opioid dependence. Cochrane Database of Systematic Reviews(3). doi: 10.1002/14651858.CD002208

Fajemirokun-Odudeyi, O., Sinha, C., Tutty, S., Pairaudeau, P., Armstrong, D., Phillips, T., & Lindow, S. W. (2006). Pregnancy outcome in women who use opiates. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 126(2), 170-175.

Faroqui, M. H., Cole, M., & Curran, J. (1983). Buprenorphine, benzodiazepines and respiratory depression. Anaesthesia, 38(10), 1002-1003.

Ferri, M., Davoli, M., & Perucci, C. A. (2011). Heroin maintenance for chronic heroin-dependent individuals. Cochrane Database of Systematic Reviews(12). doi: 10.1002/14651858.CD003410.pub4

Fiorentine, R., & Hillhouse, M. P. (2000). Self-efficacy, expectancies, and abstinence acceptance: further evidence for the addicted-self model of cessation of alcohol- and drug-dependent behaviour. American Journal of Drug and Alcohol Abuse, 26(4), 497-521.

Fischer, G., Gombas, W., Eder, H., Jagsch, R., Peternell, A., Stuhlinger, G., . . . Kasper, S. (1999). Buprenorphine versus methadone maintenance for the treatment of opioid dependence. Addiction, 94(9), 1337-1347.

Flynn, P. M., & Brown, B. S. (2008). Co-occurring disorders in substance abuse treatment: Issues and prospects. Journal of Substance Abuse Treatment, 34(1), 36-47.

Forrest, A. L. (1983). Buprenorphine and lorazepam. Anaesthesia, 38(6), 598.

Fudala, P. J., Jaffe, J. H., Dax, E. M., & Johnson, R. E. (1990). Use of buprenorphine in the treatment of opioid addiction. II. Physiologic and behavioral effects of daily and alternate-day administration and abrupt withdrawal. Clinical Pharmacology and Therapeutics, 47(4), 525-534.

Gaalema, D. E., Scott, T. L., Heil, S. H., Coyle, M. G., Kaltenbach, K., Badger, G. J., . . . Jones, H. E. (2012). Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates. Addiction, 107(Suppl 1), 53-62.

Gal, T. J. (1989). Naloxone reversal of buprenorphine-induced respiratory depression. Clinical Pharmacology and Therapeutics, 45(1), 66-71.

Galanter, M. (2006). Spirituality in Alcoholics Anonymous: A valuable adjunct to psychiatric services. Psychiatric Services, 57(3), 307-309.

Gaulier, J. M., Charvier, F., Monceaux, F., Marquet, P., & Lachatre, G. (2004). Ingestion of high-dose buprenorphine by a 4 year-old child. Journal of Toxicology - Clinical Toxicology, 42(7), 993-995.

Gerra, G., Di Petta, G., D'Amore, A., Ianotta, P., Bardicchia, F., Falorni, F., . . . Zaimovic, A. (2007). Combination of olanzapine with opioid-agonists in the treatment of heroin-addicted patients affected by comorbid schizophrenia spectrum disorders. Clinical Neuropharmacology, 30(3), 127-135.

Gerra, G., Leonardi, C., D'Amore, A., Strepparola, G., Fagetti, R., Assi, C., . . . Lucchini, A. (2006). Buprenorphine treatment outcome in dually diagnosed heroin dependent patients: a retrospective study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 30(2), 265-272.

Gerstein, D. R., Johnson, R. A., Harwood, H. J., Fountain, D., Suter, N., & Malloy, K. (1994). Evaluation Recovery Services: The California drug and alcohol treatment assessment (CALDATA). Sacramento, California: Department of Alcohol and Drug Programs.

Giacomuzzi, S., Haaser, W., Pilsz, L., & Riemer, Y. (2005). Driving impairment on buprenorphine and slow-release oral morphine in drug-dependent patients. Forensic Science International, 152(2-3), 323-324.

Gibson, J. C., & Vulliamy, A. (2010). Accidental methadone poisoning in children: a call for Canadian research action. Child Abuse and Neglect, 34(8), 553-554.

Gjersing, L., Waal, H., Caplehorn, J. R. M., Gossop, M., & Clausen, T. (2010). Staff attitudes and the associations with treatment organisation, clinical practices and outcomes in opioid maintenance treatment. BMC Health Services Research, 10, 194.

Gonzalez, J. P., & Brogden, R. N. (1988). Naltrexone: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs, 35, 192-213.

Gordon, A. (2008). Comorbidity of mental disorders and substance use: A brief guide for the primary care clinician. National Drug Strategy Monograph Series, 71. Retrieved from http://www.nationaldrugstrategy.gov.au/internet/drugstrategy/publishing.nsf/Content/mono71
Gossop, M. (2011). Treating drug misuse problems: evidence of effectiveness. London, UK: National Treatment Agency for Substance Misuse. Retrieved from www.nta.nhs.uk

Gossop, M., Griffiths, P., Bradley, B., & Strang, J. (1989). Opiate withdrawal symptoms in response to 10 day and 21 day methadone withdrawal programmes. British Journal of Psychiatry, 154, 360-363.

Gossop, M., Marsden, J., Stewart, D., & Rolfe, A. (2000). Patterns of improvement after methadone treatment: 1 year follow-up results from the National Treatment Outcome Research Study (NTORS). Drug and Alcohol Dependence, 60, 275-286.

Gossop, M., & Strang, J. (1997). Rapid anaesthetic-antagonist detoxification of heroin addicts: What origins, evidence and clinical justification? British Journal of Intensive Care, 7(2), 66-69.

Gourarier, L., Lowenstein, W., Gisselbrecht, M., Chauveau, J. M., Haas, C., & Durand, H. (1996). [Withdrawal syndrome in 2 drug addicts after intravenous injection of buprenorphine?] Syndrome de manque chez deux toxicomanes apres injection intraveineuse de buprenorphine? Presse Medicale, 25(27), 1239-1240.

Gowing, L., Ali, R., & White, J. (2009a). Buprenorphine for the management of opioid withdrawal. Cochrane Database of Systematic Reviews(3). doi: 10.1002/14651858.CD002025.pub3

Gowing, L., Ali, R., & White, J. M. (2009b). Opioid antagonists with minimal sedation for opioid withdrawal. Cochrane Database of Systematic Reviews(4). doi: 10.1002/14651858.CD002021.pub3

Gowing, L., Ali, R., & White, J. M. (2010). Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal. Cochrane Database of Systematic Reviews(1). doi: 10.1002/14651858.CD002022.pub3

Gowing, L., Farrell, M., Bornemann, R., Sullivan, L., & Ali, R. (2011). Substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database of Systematic Reviews(8). doi: 10.1002/14651858.CD004145.pub2

Gowing, L., Proudfoot, H., Henry-Edwards, S., & Teesson, M. (2001). Evidence supporting treatment: the effectiveness of interventions for illicit drug use. Canberra: Australian National Council on Drugs.

Gowing, L. R., & Ali, R. L. (2006). The place of detoxification in treatment of opioid dependence. Current Opinion in Psychiatry, 19(3), 266-270.

Greenfield, S. F., Brooks, A. J., Gordon, S. M., Green, C. A., Kropp, F., McHugh, R. K., . . . Miele, G. M. (2007). Substance abuse treatment entry, retention, and outcome in women: A review of the literature. Drug and Alcohol Dependence, 86, 1-21.

Greenwald, M. K. (2002). Heroin craving and drug use in opioid-maintained volunteers: Effects of methadone dose variations. Experimental and Clinical Psychopharmacology, 10(1), 39-46.

Grella, C. E., & Lovinger, K. (2011). 30-Year trajectories of heroin and other drug use among men and women sampled from methadone treatment in California. Drug and Alcohol Dependence, 118, 251-258.

Groh, D. R., Jason, L. A., & Keys, C. B. (2008). Social network variables in alcoholics anonymous: A literature review. Clinical Psychology Review, 28, 430-450.

Groshkova, T., Best, D., & White, W. (2013). The assessment of recovery capital: Properties and psychometrics of a measure of addiction recovery strengths. Drug and Alcohol Review, 32, 187-194.

Gruber, V. A., Delucchi, K. L., Kielstein, A., & Batki, S. L. (2008). A randomized trial of 6-month methadone maintenance with standard or minimal counseling versus 21-day methadone detoxification. Drug and Alcohol Dependence, 94(1-3), 199-206.

Hall, K., Gibbie, T., & Lubman, D. I. (2012). Motivational interviewing techniques: Facilitating behaviour change in the general practice setting. Australian Family Physician, 41(9), 660-667.

Hall, W. (1996). Methadone maintenance treatment as a crime control measure. Crime and Justice Bulletin(29).

Hall, W., Ward, J., & Mattick, R. P. (1998). The effectiveness of methadone maintenance treatment 1: Heroin use and crime. In J. Ward, R. P. Mattick & W. Hall (Eds.), Methadone Maintenance Treatment and Other Opioid Replacement Therapies (pp. 17-57). Amsterdam: Harwood Academic Publishers.

Harris, D. S., Mendelson, J. E., Lin, E. T., Upton, R. A., Jones, R. T., Harris, D. S., . . . Jones, R. T. (2004). Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone: Lack of dose proportionality. Clinical Pharmacokinetics, 43(5), 329-340.

Harrison, C. A., & Abou Saleh, M. T. (2002). Psychiatric disorders and substance misuse: psychopathology. In G. H. Rassool (Ed.), Dual diagnosis: Substance misuse and psychiatric disorders (pp. 43-57). Oxford: Blackwell Science.

Hartzler, B., Lash, S. J., & Roll, J. M. (2012). Contingency management in substance abuse treatment: A structured review of the evidence for its transportability. Drug and Alcohol Dependence, 122(1-2), 1-10.

Hedrich, D., Alves, P., Farrell, M., Stover, H., Moller, L., & Mayet, S. (2012). The effectiveness of opioid maintenance treatment in prison settings: a systematic review. Addiction, 107, 501-517.

Heinz, A., Beck, A., Grusser, S. M., Grace, A. A., & Wrase, J. (2008). Identifying the neural circuitry of alcohol craving and relapse vulnerability. Addiction Biology, 14, 108-118.

Herve, S., Riachi, G., Noblet, C., Guillement, N., Tanasescu, S., Goria, O., . . . Lerebours, E. (2004). Acute hepatitis due to buprenorphine administration. European Journal of Gastroenterology and Hepatology, 16(10), 1033-1037.

Holmwood, C., Marriott, M., & Humeniuk, R. (2008). Substance use patterns in newly admitted male and female South Australian prisoners using the WHO-ASSIST (Alcohol, Smoking and Substance Involvement Screening Test). International Journal of Prison Health, 4(4), 198-207.

Holt, M., Treloar, C., McMillan, K., Schultz, M., & Bath, N. (2007). Barriers and incentives to treatment for illicit drug users with mental health comorbidities and complex vulnerabilities. Canberra: Commonwealth of Australia.

Horgan, J. (1989). Lukewarm turkey. Scientific American, 260(3), 32.

Hubbard, R. L., Craddock, S. G., & Anderson, J. (2003). Overview of 5-year followup outcomes in the drug abuse treatment outcome studies (DATOS). Journal of Substance Abuse Treatment, 25, 125-134.

Hughes, J. (2008). An algorithm for choosing among smoking cessation treatments. Journal of Substance Abuse Treatment, 34(4), 426-432.

Humeniuk, R., Ali, R., Babor, T., Souza-Formigoni, M. L. O., Boerngen de Lacerda, R., Ling, W., . . . Vendetti, J. (2012). A randomized controlled trial of a brief intervention for illicit drugs linked to the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) in clients recruited from primary health-care settings in four countries. Addiction, 107, 957-966.

Humeniuk, R., Ali, R., McGregor, C., & Darke, S. (2003). Prevalence and correlates of intravenous methadone syrup administration in Adelaide, Australia. Addiction, 98(4), 413-418.

Humeniuk, R., Ali, R., White, J., Hall, W., & Farrell, M. (2000). Proceedings of expert workshop on the induction and stabilisation of patients onto methadone. Canberra, Australia: Commonwealth Department of Health and Aged Care.

Jacobs, E. A., & Bickel, W. K. (1999). Precipitated withdrawal in an opioid-dependent outpatient receiving alternate-day buprenorphine dosing. Addiction, 94(1), 140-141.

Jansson, L. M., Choo, R., Velez, M. L., Harrow, C., Schroeder, J. R., Shakleya, D. M., & Huestis, M. A. (2008). Methadone maintenance and breastfeeding in the neonatal period. Pediatrics, 121, 106-114.

Jansson, L. M., Di Pietro, J. A., Elko, A., Williams, E. L., Milio, L., & Velez, M. (2012). Pregnancies exposed to methadone, methadone and other illicit substances, and poly-drugs without methadone: A comparison of fetal neurobehaviors and infant outcomes. Drug and Alcohol Dependence, 122(3), 213-219.

Jansson, L. M., Velez, M., & Harrow, C. (2009). The opioid-exposed newborn: assessment and pharmacologic management. Journal of Opioid Management, 5(1), 47-55.

Jasinski, D. R. (1981). Opiate withdrawal syndrome: acute and protracted aspects. Annals of the New York Academy of Sciences, 362, 183-190.

Jasinski, D. R., Haertzen, C. A., Henningfield, J. E., Johnson, R. E., Makhzoumi, H. M., & Miyasato, K. (1982). Progress report of the NIDA Addiction Research Center. NIDA Research Monograph, 41, 45-52.

Jaudes, P. K., Ekwo, E., & Van, V. J. (1995). Association of drug abuse and child abuse. Child Abuse and Neglect, 19(9), 1065-1075.

Johnson, R. E., Eissenberg, T., Stitzer, M. L., Strain, E. C., Liebson, I. A., & Bigelow, G. E. (1995). Buprenorphine treatment of opioid dependence: clinical trial of daily versus alternate-day dosing. Drug and Alcohol Dependence, 40(1), 27-35.

Johnson, R. E., Strain, E. C., & Amass, L. (2003). Buprenorphine: how to use it right. Drug and Alcohol Dependence, 70(Suppl. 2), S59-S77.

Jones, H. E., Heil, S. H., Baewert, A., Arria, A. M., Kaltenbach, K., Martin, P. R., . . . Fischer, G. (2012). Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review. Addiction, 107(Suppl 1), 5-27.

Jones, H. E., Kaltenbach, K., Heil, S. H., & Stine, S. M. (2010). Neonatal abstinence syndrome after methadone or buprenorphine exposure. New England Journal of Medicine, 363(24), 2320-2331.

Jones, H. E., O'Grady, K. E., Malfi, D., & Tuten, M. (2008). Methadone maintenance vs. methadone taper during pregnancy: Maternal and neonatal outcomes. American Journal on Addictions, 17(5), 372-386.

Jurgens, R. (2007). Interventions to address HIV in prisons: Drug dependence treatments. Geneva: World Health Organization.

Kakko, J., Heilig, M., & Sarman, I. (2008). Buprenorphine and methadone treatment of opiate dependence during pregnancy: Comparison of fetal growth and neonatal outcomes in two consecutive case series. Drug and Alcohol Dependence, 96, 69-78.

Kakko, J., Svanborg, K. D., Kreek, M. J., & Heilig, M. (2003). 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet, 361(9358), 662-668.

Kaltenbach, K., Berghella, V., & Finnegan, L. (1998). Opioid dependence during pregnancy: effects and management. Obstetrics and Gynecology Clinics of North America, 25(1), 139-152.

Kaltenbach, K., Holbrook, A. M., Coyle, M. G., Heil, S. H., Salisbury, A. L., Stine, S. M., . . . Jones, H. E. (2012). Predicting treatment for neonatal abstinence syndrome in infants born to women maintained on opioid agonist medication. Addiction, 107(Suppl 1), 45-52.

Kaskutas, L. A. (2009). Alcoholics Anonymous effectiveness: Faith meets science. Journal of Addictive Diseases, 28, 145-157.

Kaskutas, L. A., Zhang, L., French, M. T., & Witbrodt, J. (2005). Women's programs versus mixed-gender day treatment: results from a randomized study. Addiction, 100(1), 60-69.

Keene, J. (2005). A case-linkage study of the relationship between drug misuse, crime, and psychosocial problems in a total criminal justice population. Addiction Research and Theory, 13(5), 489-502.

Keene, J., Stenner, K., Connor, M., & Fenley, S. (2007). A case-study of substitute opiate prescribing for drug-using offenders. Drugs: Education, Prevention & Policy, 14(5), 443-456.

Kelly, J. F., Magill, M., & Stout, R. L. (2009). How do people recover from alcohol dependence? A systematic review of the research on mechanisms of behavior change in Alcoholics Anonymous. Addiction Research & Theory, 17(3), 236-259.

Kelly, S. M., Schwartz, R. P., O'Grady, K. E., Gandhi, D., & Jaffe, J. J. (2012). Impact of methadone with versus without drug abuse counseling on HIV risk: 4- and 12-month findings from a clinical trial. Journal of Addiction Medicine, 6(2), 145-152.

Knape, J. T. (1986). Early respiratory depression resistant to naloxone following epidural buprenorphine. Anesthesiology, 64(3), 382-384.

Koob, G. F., & Volkow, N. D. (2010). Neurocircuitry of addiction. Neuropsychopharmacology Reviews, 35, 217-238.

Kornor, H., Waal, H., & Ali, R. L. (2006). Abstinence-orientated buprenorphine replacement therapy for young adults in out-patient counselling. Drug & Alcohol Review, 25(2), 123-130.

Kosten, T. R., Morgan, C., & Kleber, H. D. (1991). Treatment of heroin addicts using buprenorphine. American Journal of Drug and Alcohol Abuse, 17(2), 119-128.

Kosten, T. R., Rounsaville, B. J., & Kleber, H. D. (1985). Comparison of clinician ratings to self reports of withdrawal during clonidine detoxification of opiate addicts. American Journal of Drug and Alcohol Abuse, 11(1-2), 1-10.

Kosten, T. R., Schottenfeld, R., Ziedonis, D., & Falcioni, J. (1993). Buprenorphine versus methadone maintenance for opioid dependence. Journal of Nervous and Mental Disease, 181(6), 358-364.

Kreek, M. J. (2000). Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine. Annals of the New York Academy of Sciences, 909, 186-216.

Kreek, M. J., Borg, L., Ducat, E., & Ray, B. (2010). Pharmacotherapy in the treatment of addiction: Methadone. Journal of Addictive Diseases, 29(2), 209-216.

Krentzman, A. R., Robinson, E. A., Moore, B. C., Kelly, J. F., Laudet, A. B., White, W. L., . . . Strobbe, S. (2011). How Alcoholics Anonymous (AA) and Narcotics Anonymous (NA) work: Cross-disciplinary perspectives. Alcoholism Treatment Quarterly, 29, 75-84.

Kroll, B. (2004). Living with an elephant: Growing up with parental substance misuse. Child & Family Social Work, 9(2), 129-140.

Kuhlman, J. J., Levine, B., Johnson, R. E., Fudala, P. J., & Cone, E. J. (1998). Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine. Addiction, 93(4), 549-559.

Kunoe, N., Lobmaier, P., Vederhus, J. K., Hjerkinn, B., Hegstad, S., Gossop, M., . . . Waal, H. (2009). Naltrexone implants after in-patient treatment for opioid dependence: randomised controlled trial. British Journal of Psychiatry, 194(6), 541-546.

Larance, B., Degenhardt, L., Lintzeris, N., Bell, J., Winstock, A., Dietze, P., . . . Horyniak, D. (2011). Post-marketing surveillance of buprenorphine-naloxone in Australia: Diversion, injection and adherence with supervised dosing. Drug and Alcohol Dependence, 118(2-3), 265-273.

Lowinson, J. H., Payte, J. T., Salsitz, E., Joseph, H., Marion, I. J., and Dole, V. P. (1997.) Methadone maintenance. In J. H. Lowinson, J. T. Payte, E. Salsitz, H. Joseph, I. J. Marion, and V. P. Dole (Eds.), Substance Abuse: a comprehensive text (3rd ed.., pp. 405-415). Baltimore: Williams and Wilkins.

Lee, M. C., Wagner, H. N., Tanada, S., Frost, J. J., Bice, A. N., & Dannals, R. F. (1988). Duration of occupancy of opiate receptors by naltrexone. Journal of Nuclear Medicine, 29(7), 1207-1211.

Lenne, M. G., Dietze, P., Rumbold, G. R., Redman, J. R., & Triggs, T. J. (2003). The effects of the opioid pharmacotherapies methadone, LAAM and buprenorphine, alone and in combination with alcohol, on simulated driving. Drug and Alcohol Dependence, 72(3), 271-278.

Lerner, A. G., Gelkopf, M., Oyffe, I., & Sigal, M. (1995). Home-based inpatient treatment vs. outpatient day clinic treatment: a preliminary report in opiate-dependent patients. Journal of Nervous and Mental Disease, 183(11), 715.

Leung, S. Y. (2011). Benzodiazepines, opioids and driving: an overview of the experimental research. Drug & Alcohol Review, 30(3), 281-286.

Levy, S., Vaughan, B. L., Angulo, M., & Knight, J. R. (2007). Buprenorphine replacement therapy for adolescents with opioid dependence: Early experience from a children's hospital-based outpatient treatment program. Journal of Adolescent Health, 40(5), 477-482.

Ling, W., Charuvastra, C., Collins, J. F., Batki, S., Brown, L. S., Kintaudi, P., . . . Segal, D. (1998). Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction, 93(4), 475-486.

Ling, W., Farabee, D., Liepa, D., & Wu, L.-T. (2012). The Treatment Effectiveness Assessment (TEA): an efficient, patient-centered instrument for evaluating progress in recovery from addiction. Substance Abuse and Rehabilitation, 3, 129-136.

Lingford-Hughes, A., & Nutt, D. (2003). Neurobiology of addiction and implications for treatment. British Journal of Psychiatry, 182, 97-100.

Lingford-Hughes, A. R., Welch, S., Peters, L., & Nutt, D. J. (2012). BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP. Journal of Psychopharmacology, 26(7), 899-952.

Lintzeris, N., Leung, S. Y., Dunlop, A. J., Larance, B., White, N., Rivas, G. R., . . . Ali, R. (2013). A randomised controlled trial of sublingual buprenorphine-naloxone film versus tablets in the management of opioid dependence. Drug and Alcohol Dependence, (in press).

Lofwall, M. R., Stitzer, M. L., Bigelow, G. E., & Strain, E. C. (2005). Comparative safety and side effect profiles of buprenorphine and methadone in the outpatient treatment of opioid dependence. Addictive Disorders & Their Treatment, 4(2), 49-64.

MacArthur, G. J., Minozzi, S., Martin, N., Vickerman, P., Deren, S., Bruneau, J., . . . Hickman, M. (2012). Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ, 345, e5945.

Madlung-Kratzer, E., Spitzer, B., Brosch, R., Dunkel, D., & Haring, C. (2009). A double-blind, randomized, parallel group study to compare the efficacy, safety and tolerability of slow-release oral morphine versus methadone in opioid-dependent in-patients willing to undergo detoxification. Addiction, 104, 1549-1557.

Magura, S., & Rosenblum, A. (2001). Leaving methadone treatment: lessons learned, lessons forgotten, lessons ignored. Mount Sinai Journal of Medicine, 68(1), 62-74.

Malta, M., Strathdee, S. A., Magnanini, M. M., & Bastos, F. I. (2008). Adherence to antiretroviral therapy for human immunodeficiency virus/acquired immune deficiency syndrome among drug users: a systematic review. Addiction, 103, 1242-1257.

Martell, B. A., Arnsten, J. H., Ray, B., & Gourevitch, M. N. (2003). The impact of methadone induction on cardiac conduction in opiate users. Annals of Internal Medicine, 139(2), 154-155.

Martin, J. A., Campbell, A., Killip, T., Kotz, M., Krantz, M. J., Kreek, M. J., . . . Administration, S. A. a. M. H. S. (2011). QT interval screening in methadone maintenance treatment: report of a SAMHSA expert panel. Journal of Addictive Diseases, 30(4), 283-306.

Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2009). Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database of Systematic Reviews(3), CD002209. doi: 10.1002/14651858.CD002209.pub2

Mattick, R. P., Kimber, J., Breen, C., & Davoli, M. (2008). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews(2), CD002207. doi: 10.1002/14651858.CD002207.pub3

Mayes, L. C., & Bornstein, M. H. (1996). The context of development for young children from cocaine-abusing families. In P. M. Kato & T. Mann (Eds.), Handbook of Diversity Issues in Health Psychology (pp. 69-95). New York, USA: Springer.

McCambridge, J., & Strang, J. (2004). The efficacy of single-session motivational interviewing in reducing drug consumption and perceptions of drug-related risk and harm among young people: results from a multi-site cluster random,ized trial. Addiction, 99(1), 39-52.

McDonald, S. D., Vermeulen, M. J., & Ray, J. G. (2007). Risk of fetal death associated with maternal drug dependence and placental abruption: a population-based study. Journal of Obstetrics and Gynaecology Canada, 29(7), 556-559.

McLellan, A. T., Lewis, D. C., O'Brien, C. P., & Kleber, H. D. (2000). Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. Journal of the American Medical Association, 284(13), 1689-1695.

Mello, N. K., & Mendelson, J. H. (1980). Buprenorphine suppresses heroin use by heroin addicts. Science, 207(4431), 657-659.

Mendelson, J., & Jones, R. T. (2003). Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: Why the 4:1 ratio for treatment? Drug and Alcohol Dependence, 70(Suppl), S29-S37.

Merlo, L. J., Greene, W. M., & Pomm, R. (2011). Mandatory naltrexone treatment prevents relapse among opiate-dependent anesthesiologists returning to practice. Journal of Addiction Medicine, 5(4), 279-283.

Miller, W. R., & Rollnick, S. (1991). Motivational interviewing: Preparing people to change addictive behavior. New York: The Guilford Press.

Mills, K. L., Lynskey, M., Teesson, M., Ross, J., & Darke, S. (2005). Post-traumatic stress disorder among people with heroin dependence in the Australian treatment outcome study (ATOS): prevalence and correlates. Drug and Alcohol Dependence, 77(3), 243-249.

Minozzi, S., Amato, L., Vecchi, S., Davoli, M., Kirchmayer, U., & Verster, A. (2011). Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database of Systematic Reviews(4). doi: 10.1002/14651858.CD001333.pub4

Mintzer, M. Z., Correia, C. J., & Strain, E. C. (2004). A dose-effect study of repeated administration of buprenorphine/naloxone on performance in opioid-dependent volunteers. Drug and Alcohol Dependence, 74, 205-209.

Mitchell, S. G., Gryczynski, J., Schwartz, R. P., O'Grady, K. E., Olsen, Y. K., & Jaffe, J. H. (2013). A randomized trial of intensive outpatient (IOP) vs. standard outpatient (OP) buprenorphine treatment for African Americans. Drug and Alcohol Dependence, 128(3), 222-229.

Montoya, I. D., Gorelick, D. A., Preston, K. L., Schroeder, J. R., Umbricht, A., Cheskin, L. J., . . . Fudala, P. J. (2004). Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence. Clinical Pharmacology and Therapeutics, 75(1), 34-38.

Moody, D. E., Fang, W. B., Morrison, J., & McCance-Katz, E. (2011). Gender differences in pharmacokinetics of maintenance dosed buprenorphine. Drug and Alcohol Dependence, 118, 479-483.

Moore, S. K., Marsch, L. A., Badger, G. J., Solhkah, R., & Hofstein, Y. (2011). Improvement in psychopathology among opioid-dependent adolescents during behavioral-pharmacological treatment. Journal of Addiction Medicine, 5(4), 264-271.

Moreno, A., Perez-Elias, M. J., Casado, J. L., Munoz, V., Antela, A., Dronda, F., . . . Moreno, S. (2001). Long-term outcomes of protease inhibitor-based therapy in antiretroviral treatment-naive HIV-infected injection drug users on methadone maintenance programmes. AIDS, 15(8), 1068-1070.

Moss, A. J. (2006). QTc prolongation and sudden cardiac death: The association is in the detail. Journal of the American College of Cardiology, 47(2), 368-369.

Mudric, T. D., Strain, E. C., Stitzer, M. L., & Bigelow, G. E. (1998). Gradual buprenorphine detoxification in an outpatient clinic. NIDA Research Monograph, 179, 228.

Mysels, D. J., Cheng, W. Y., Nunes, E. V., & Sullivan, M. A. (2011). The association between naltrexone treatment and symptoms of depression in opioid-dependent patients. American Journal of Drug and Alcohol Abuse, 37(1), 22-26.

National Treatment Agency for Substance Misuse. (2002). Models of care for the treatment of drug misusers. Part 2: Full reference report. London, UK: Department of Health. Retrieved from www.nta.nhs.uk

National Treatment Agency for Substance Misuse. (2006). Models of care for treatment of adult drug misusers: Update 2006. London, UK: Department of Health.

Nosyk, B., Sun, H., Evans, E., Marsh, D. C., Anglin, M. D., Hser, Y.-I., & Anis, A. H. (2012). Defining dosing pattern characteristics of successful tapers following methadone maintenance treatment: Results from a population-based retrospective cohort study. Addiction, 107, 1621-1629.

Nunes, E. V., & Levin, F. R. (2004). Treatment of depression in patients with alcohol or other drug dependence: A meta-analysis. Journal of the American Medical Association, 291(15), 1887-1896.

Oliver, P., Keen, J., Rowse, G., Ewins, E., Griffiths, L., & Mathers, N. (2010). The effect of time spent in treatment and dropout status on rates of convictions, cautions and imprisonment over 5 years in a primary care-led methadone maintenance service. Addiction, 105(4), 732-739.

Osborn, D. A., Jeffery, H. E., & Cole, M. J. (2010a). Opiate treatment for opiate withdrawal in newborn infants. Cochrane Database of Systematic Reviews(10). doi: 10.1002/14651858.CD002059.pub3

Osborn, D. A., Jeffery, H. E., & Cole, M. J. (2010b). Sedatives for opiate withdrawal in newborn infants. Cochrane Database of Systematic Reviews(10). doi: 10.1002/14651858.CD002053.pub3

Palmiere, C., Staub, C., La, H. R., & Mangin, P. (2010). Parental substance abuse and accidental death in children. Journal of Forensic Sciences, 55(3), 819-821.

Pani, P. P., Vacca, R., Trogu, E., Amato, L., & Davoli, M. (2010). Pharmacological treatment for depression during opioid agonist treatment for opioid dependence. Cochrane Database of Systematic Reviews(9). doi: 10.1002/14651858.CD008373.pub2

Papworth, D. P. (1983). High dose buprenorphine for postoperative analgesia. Anaesthesia, 38(2), 163.

Peles, E., Schreiber, S., & Adelson, M. (2009). Documented poor sleep among methadone-maintained patients is associated with chronic pain and benzodiazepine abuse, but not with methadone dose. European Neuropsychopharmacology, 19(8), 581-588.

Peles, E., Schreiber, S., Bloch, M., Dollberg, S., & Adelson, M. (2012). Duration of methadone maintenance treatment during pregnancy and pregnancy outcome parameters in women with opiate addiction. Journal of Addiction Medicine, 6(1), 18-23.

Perez de los Cobos, J., Martin, S., Etcheberrigaray, A., Trujols, J., Batlle, F., Tejero, A., . . . Casas, M. (2000). A controlled trial of daily versus thrice-weekly buprenorphine administration for the treatment of opioid dependence. Drug and Alcohol Dependence, 59(3), 223-233.

Petry, N. M., Bickel, W. K., & Badger, G. J. (1999). A comparison of four buprenorphine dosing regimens in the treatment of opioid dependence. Clinical Pharmacology and Therapeutics, 66(3), 306-314.

Petry, N. M., Bickel, W. K., & Badger, G. J. (2000). A comparison of four buprenorphine dosing regimens using open-dosing procedures: is twice-weekly dosing possible? Addiction, 95(7), 1069-1077.

Prendergast, M. L., Messina, N. P., Hall, E. A., & Warda, U. S. (2011). The relative effectiveness of women-only and mixed-gender treatment for substance-abusing women. Journal of Substance Abuse Treatment, 40, 336-348.

Prochaska, J. J., Delucchi, K., & Hall, S. M. (2004). A meta-analysis of smoking cessation interventions with individuals in substance abuse treatment or recovery. Journal of Consulting and Clinical Psychology, 72(6), 1144-1156.

Prochaska, J. O., DiClemente, C. C., & Norcross, J. C. (1997). In search of how people change: applications to addictive behaviors. In G. A. Marlatt & G. R. VandenBos (Eds.), Addictive Behaviors: Readings on etiology, prevention and treatment (pp. 671-696). Washington DC: American Psychological Association.

Quigley, A. J., Bredemeyer, D. E., & Seow, S. S. (1984). A case of buprenorphine abuse. Medical Journal of Australia, 140(7), 425-426.

Rapeli, P., Fabritius, C., Alho, H., Salaspuro, M., Wahlbeck, K., & Kalska, H. (2007). Methadone vs. buprenorphine/naloxone during early opioid substitution treatment: A naturalistic comparison of cognitive performance relative to healthy controls. BMC Clinical Pharmacology, 7, 5.

Rapeli, P., Fabritius, C., Kalska, H., & Alho, H. (2011). Cognitive functioning in opioid-dependent patients treated with buprenorphine, methadone, and other psychoactive medications: stability and correlates. BMC Clinical Pharmacology, 11, 13.

Reid, M. S., Fallon, B., Sonne, S., Flammino, F., Nunes, E. V., Jiang, H., . . . Rotrosen, J. (2008). Smoking cessation treatment in community-based substance abuse rehabilitation programs. Journal of Substance Abuse Treatment, 35, 68-77.

Resnick, R. B., Galanter, M., Pycha, C., Cohen, A., Grandison, P., & Flood, N. (1992). Buprenorphine: an alternative to methadone for heroin dependence treatment. Psychopharmacology Bulletin, 28(1), 109-113.

Rhoades, H. M., Creson, D., Elk, R., Schmitz, J., & Grabowski, J. (1998). Retention, HIV risk, and illicit drug use during treatment: Methadone dose and visit frequency. American Journal of Public Health, 88(1), 34-39.

Robertson, J. R., Raab, G. M., Bruce, M., McKenzie, J. S., Storkey, H. R., & Salter, A. (2006). Addressing the efficacy of dihydrocodeine versus methadone as an alternative maintenance treatment for opiate dependence: A randomized controlled trial. Addiction, 101(12), 1752-1759.

Roozen, H. G., Boulogne, J. J., van Tulder, M. W., van den Brink, W., De Jong, C. A., & Kerkhof, A. J. (2004). A systematic review of the effectiveness of the community reinforcement approach in alcohol, cocaine and opioid addiction. Drug and Alcohol Dependence, 74(1), 1-13.

Rosado, J., Walsh, S. L., Bigelow, G. E., & Strain, E. C. (2007). Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone. Drug and Alcohol Dependence, 90(2-3), 261-269.

Rosen, M., & Kosten, T. R. (1995). Detoxification and induction onto naltrexone. In A. Cowan & J. W. Lewis (Eds.), Buprenorphine: Combatting drug abuse with a unique opioid (pp. 289-305). New York: Wiley-Liss.

Rosen, T. S., & Johnson, H. L. (1982). Children of methadone-maintained mothers: Follow-up to 18 months of age. Journal of Pediatrics, 101(2), 192-196.

Rosner, S., Hackl-Herrwerth, A., Leucht, S., Vecchi, S., Srisurapanont, M., & Soyka, M. (2010). Opioid antagonists for alcohol dependence. Cochrane Database of Systematic Reviews, 8. doi: 10.1002/14651858.CD001867.pub3

Roux, P., Carrieri, M. P., Cohen, J., Ravaux, I., Poizot-Martin, I., Dellamonica, P., & Spire, B. (2009). Retention in opioid substitution treatment: A major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment. Clinical Infectious Diseases, 49(9), 1433-1440.

Roy, A. K., McCarthy, C., Kiernan, G., McGorrian, C., Keenan, E., Mahon, N. G., & Sweeney, B. (2012). Increased incidence of QT interval prolongation in a population receiving lower doses of methadone maintenance therapy. Addiction, 107(6), 1132-1139.

Ruetsch, C., Tkacz, J., McPherson, T. L., & Cacciola, J. (2012). The effect of telephonic patient support on treatment for opioid dependence: Outcomes at one year follow-up. Addictive Behaviors, 37(5), 686-689.

San, L., Cami, J., Fernandez, T., Olle, J. M., Peri, J. M., & Torrens, M. (1992). Assessment and management of opioid withdrawal symptoms in buprenorphine dependent subjects. British Journal of Addiction, 87(1), 55-62.

Saxon, A. J., Ling, W., Hillhouse, M., Thomas, C., Hasson, A., Ang, A., . . . Jacobs, P. (2013). Buprenorphine/Naloxone and methadone effects on laboratory indices of liver health: A randomized trial. Drug and Alcohol Dependence, 128(1-2), 71-76.

Schisler, R. E., Groninger, H., & Rosielle, D. A. (2012). Counseling patients on side effects and driving when starting opioids #248. Journal of Palliative Medicine, 15(4), 484-485.

Schottenfeld, R. S., Pakes, J., O'Connor, P., Chawarski, M., Oliveto, A., & Kosten, T. R. (2000). Thrice-weekly versus daily buprenorphine maintenance. Biological Psychiatry, 47(12), 1072-1079.

Schottenfeld, R. S., Pakes, J., Ziedonis, D., & Kosten, T. R. (1993). Buprenorphine: dose-related effects on cocaine and opioid use in cocaine-abusing opioid-dependent humans. Biological Psychiatry, 34(1-2), 66-74.

Schottenfeld, R. S., Pakes, J. R., Oliveto, A., Ziedonis, D., & Kosten, T. R. (1997). Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Archives of General Psychiatry, 54(8), 713-720.

Schwartz, R. P., Kelly, S. M., O'Grady, K. E., Gandhi, D., & Jaffe, J. J. (2012). Randomized trial of standard methadone treatment compared to initiating methadone without counseling: 12-month findings. Addiction, 107, 943-952.

Scott, J., Gilvarry, E., & Farrell, M. (1998). Managing anxiety and depression in alcohol and drug dependence. Addictive Behaviors, 23(6), 919-931.

Sees, K. L., Delucchi, K. L., Masson, C., Rosen, A., Clark, H. W., Robillard, H., . . . Hall, S. M. (2000). Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: A randomized controlled trial. Journal of the American Medical Association, 283(10), 1303-1310.

Sekar, M., & Mimpriss, T. J. (1987). Buprenorphine, benzodiazepines and prolonged respiratory depression. Anaesthesia, 42(5), 567-568.

Seligman, N. S., Almario, C. V., Hayes, E. J., Dysart, K. C., Berghella, V., & Baxter, J. K. (2010). Relationship between maternal methadone dose at delivery and neonatal abstinence syndrome. Journal of Pediatrics, 157(3), 428-433.

Seow, S. S., Quigley, A. J., Ilett, K. F., Dusci, L. J., Swensen, G., Harrison-Stewart, A., & Rappeport, L. (1986). Buprenorphine: A new maintenance opiate? Medical Journal of Australia, 144(8), 407-411.

Shand, F., Gates, J., Fawcett, J., & Mattick, R. (2003). The treatment of alcohol problems. A review of the evidence. Canberra: Commonwealth of Australia.

Shmygalev, S., Damm, M., Weckbecker, K., Berghaus, G., Petzke, F., & Sabatowski, R. (2011). The impact of long-term maintenance treatment with buprenorphine on complex psychomotor and cognitive function. Drug and Alcohol Dependence, 117, 190-197.

Sigmon, S. C., Bisaga, A., Nunes, E. V., O'Connor, P. C., Kosten, T., & Woody, G. (2012). Opioid detoxification and naltrexone induction strategies: Recommendations for clinical practice. American Journal of Drug and Alcohol Abuse, 38(3), 187-199.

Simon, D. L. (1997). Rapid opioid detoxification using opioid antagonists: history, theory and the state of the art. Journal of Addictive Diseases, 16(1), 103-122.

Simpson, D. D., Joe, G. W., Greener, J. M., & Rowan-Szal, G. A. (2000). Modeling year 1 outcomes with treatment process and post-treatment social influences. Substance Use and Misuse, 35(12-14), 1911-1930.

Smith, D. K., Johnson, A. B., Pears, K. C., Fisher, P. A., & DeGarmo, D. S. (2007). Child maltreatment and foster care: unpacking the effects of prenatal and postnatal parental substance use. Child Maltreatment, 12(2), 150-160.

Smyth, B. P., Fagan, J., & Kernan, K. (2012). Outcome of heroin-dependent adolescents presenting for opiate substitution treatment. Journal of Substance Abuse Treatment, 42(1), 35-44.

Soyka, M., Hock, B., Kagerer, S., Lehnert, R., Limmer, C., & Kuefner, H. (2005). Less impairment on one portion of a driving-relevant psychomotor battery in buprenorphine-maintained than in methadone-maintained patients: results of a randomized clinical trial. Journal of Clinical Psychopharmacology, 25(5), 490-493.

Soyka, M., Lieb, M., Kagerer, S., Zingg, C., Koller, G., Lehnert, P., . . . Hennig-Fast, K. (2008). Cognitive functioning during methadone and buprenorphine treatment: results of a randomized clinical trial. Journal of Clinical Psychopharmacology, 28(6), 699-703.

Spire, B., Lucas, G. M., & Carrieri, M. P. (2007). Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST). International Journal of Drug Policy, 18, 262-270.

Spooner, C. (1999). Causes and correlates of adolescent drug abuse and implications for treatment. Drug and Alcohol Review, 18(4), 453-475.

Staedt, J., Wassmuth, F., Stoppe, G., Hajak, G., Rodenbeck, A., Poser, W., & Ruther, E. (1996). Effects of chronic treatment with methadone and naltrexone on sleep in addicts. European Archives of Psychiatry and Clinical Neuroscience, 246(6), 305-309.

Stallvik, M., Nordstrand, B., Kristensen, Ø., Bathen, J., Skogvoll, E., & Spigset, O. (2013). Corrected QT interval during treatment with methadone and buprenorphine - Relation to doses and serum concentrations. Drug and Alcohol Dependence, 129(1-2), 88-93.

Stallwitz, A., & Stover, H. (2007). The impact of substitution treatment in prisons - a literature review. International Journal of Drug Policy, 18, 464-474.

Stein, M. R., Soloway, I. J., Jefferson, K. S., Roose, R. J., Arnsten, J. H., & Litwin, A. H. (2012). Concurrent group treatment for hepatitis C: Implementation and outcomes in a methadone maintenance treatment program. Journal of Substance Abuse Treatment, 43(4), 424-432.

Stewart, S. H., Pihl, R. O., Conrod, P. J., & Dongier, M. (1998). Functional associations among trauma, PTSD, and substance-related disorders. Addictive Behaviors, 23(6), 797-812.

Stimson, G. V. (1995). AIDS and injecting drug use in the United Kingdom, 1987-1993: the policy response and the prevention of the epidemic. Social Science and Medicine, 41(5), 699-716.

Strain, E. C., Moody, D. E., Stoller, K. B., Walsh, S. L., & Bigelow, G. E. (2004). Relative bioavailability of different buprenorphine formulations under chronic dosing conditions. Drug and Alcohol Dependence, 74(1), 37-43.

Strand, M. C., Fjeld, B., Arnestad, M., & Mørland, J. (2013). Can patients receiving opioid maintenance therapy safely drive? A systematic review of epidemiological and experimental studies on driving ability with a focus on concomitant methadone or buprenorphinie administration. Traffic Injury Prevention, 14, 26-38.

Straus, S. M. J. M., Kors, J. A., De Bruin, M. L., van der Hooft, C. S., Hofman, A., Heeringa, J., . . . Witteman, J. C. M. (2006). Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. Journal of the American College of Cardiology, 47(2), 362-367.

Street, K., Harrington, J., Chiang, W., Cairns, P., & Ellis, M. (2004). How great is the risk of abuse in infants born to drug-using mothers? Child: Care, Health and Development, 30(4), 325-330.

Stubbs, M., Hides, L., Howard, J., & Arcuri, A. (2004). Psychostimulants and young people. In A. Baker, N. K. Lee & L. Jenner (Eds.), Models of intervention and care for psychostimulant users (pp. 133-153). Canberra: Commonwealth of Australia.

Sullivan, L. E., & Fiellin, D. A. (2004). Hepatitis C and HIV infections: implications for clinical care in injection drug users. American Journal on Addictions, 13, 1-20.

Swindle, R. W., Peterson, K. A., Paradise, M. J., & Moos, R. H. (1995). Measuring substance abuse program treatment orientations: The Drug and Alcohol Program Treatment Inventory. Journal of Substance Abuse, 7, 61-78.

Teesson, M., Havard, A., Ross, J., & Darke, S. (2006). Outcomes after detoxification for heroin dependence: findings from the Australian Treatment Outcome Study (ATOS). Drug & Alcohol Review, 25(3), 241-247.

Teesson, M., Mills, K., Ross, J., Darke, S., Williamson, A., & Havard, A. (2008). The impact of treatment on 3 years' outcome for heroin dependence: findings from the Australian Treatment Outcome Study (ATOS). Addiction, 103(1), 80-88.

Teesson, M., Ross, J., Darke, S., Lynskey, M., Ali, R., Ritter, A., & Cooke, R. (2006). One year outcomes for heroin dependence: Findings from the Australian Treatment Outcome Study (ATOS). Drug and Alcohol Dependence, 83(2), 174-180.

Teichtahl, H., Prodromidis, A., Miller, B., Cherry, G., & Kronborg, I. (2001). Sleep-disordered breathing in stable methadone programme patients: a pilot study. Addiction, 96(3), 395-403.

Thorn, S. E., Rawal, N., & Wennhager, M. (1988). Prolonged respiratory depression caused by sublingual buprenorphine. Lancet, 1(8578), 179-180.

Tiffany, S. T., Carter, B. L., & Singleton, E. G. (2000). Challenges in the manipulation, assessment and interpretation of craving relevant variables. Addiction, 95(Suppl 2), S177-S187.

Tucker, T., Ritter, A., Maher, C., & Jackson, H. (2004). Naltrexone maintenance for heroin dependence: uptake, attrition and retention. Drug & Alcohol Review, 23(3), 299-309.

Tucker, T. K., & Ritter, A. J. (2000). Naltrexone in the treatment of heroin dependence: a literature review. Drug and Alcohol Review, 19(1), 73-82.

Umbricht, A., Montoya, I. D., Hoover, D. R., Demuth, K. L., Chiang, C. T., & Preston, K. L. (1999). Naltrexone shortened opioid detoxification with buprenorphine. Drug and Alcohol Dependence, 56(3), 181-190.

UNAIDS. (2010). Global report: UNAIDS report on the global AIDS epidemic. Joint United Nations Programme on HIV/AIDS. Retrieved from www.unaids.org

UNODC. (2003). Drug abuse treatment and rehabilitation: A practical planning and implementation guide. Vienna: United Nations Office on Drugs and Crime.

Velez, M. L., Jansson, L. M., Montoya, I. D., Schweitzer, W., Golden, A., & Svikis, D. (2004). Parenting knowledge among substance abusing women in treatment. Journal of Substance Abuse Treatment, 27(3), 215-222.

Wachman, E. M., Newby, P. K., Vreeland, J., Byun, J., Bonganzi, A., Bauchner, H., & Philipp, B. L. (2011). The relationship between maternal opioid agonists and psychiatric medications on length of hospitalization for neonatal abstinence syndrome. Journal of Addiction Medicine, 5(4), 293-299.

Walsh, S. L., Preston, K. L., Bigelow, G. E., & Stitzer, M. L. (1995). Acute administration of buprenorphine in humans: partial agonist and blockade effects. Journal of Pharmacology and Experimental Therapeutics, 274(1), 361-372.

Walsh, S. L., Preston, K. L., Stitzer, M. L., Cone, E. J., & Bigelow, G. E. (1994). Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clinical Pharmacology and Therapeutics, 55(5), 569-580.

Ward, J., Mattick, R. P., & Hall, W. (1998). How long is long enough? Answers to questions about the duration of methadone maintenance treatment. In J. Ward, R. P. Mattick & W. Hall (Eds.), Methadone Maintenance Treatment and Other Opioid Replacement Therapies (pp. 305-336). Amsterdam: Harwood Academic Publishers.

Washton, A. M., Pottash, A. C., & Gold, M. S. (1984). Naltrexone in addicted business executives and physicians. Journal of Clinical Psychiatry, 45(9), 39-41.

Weiss, R. D., Griffin, M. L., Najavits, L. M., Hufford, C., Kogan, J., Thompson, H. J., . . . Siqueland, L. (1996). Self-help activities in cocaine dependent patients entering treatment: results from NIDA collaborative cocaine treatment study. Drug and Alcohol Dependence, 43(1-2), 79-86.

Welle-Strand, G. K., Skurtveit, S., Jones, H. E., Waal, H., Bakstad, B., Bjarko, L., & Ravndal, E. (2013). Neonatal outcomes following in utero exposure to methadone or buprenorphine: A national cohort study of opioid-agonist treatment of pregnant women in Norway from 1996 to 2009. Drug and Alcohol Dependence, 127(1-3), 200-206.

WHO. (2009). Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Geneva, Switzerland: World Health Organization, Department of Mental Health and Substance Abuse.

Williams, H. (2002). Dual Diagnosis - an overview: Fact or fiction? In G. H. Rassool (Ed.), Dual Diagnosis: Substance Misuse and Psychiatric Disorders (pp. 3-11). Oxford: Blackwell Science.

Winstock, A. R., Lintzeris, N., & Lea, T. (2011). "Should I stay or should I go?" Coming off methadone and buprenorphine treatment. International Journal of Drug Policy, 22(1), 77-81.

Witkiewitz, K., Bowen, S., Douglas, H., & Hsu, S. H. (2013). Mindfulness-based relapse prevention for substance craving. Addictive Behaviors, 38(2), 1563-1571.

Woody, G. E., Poole, S. A., Subramaniam, G., Dugosh, K., Bogenschutz, M., Abbott, P., . . . Fudala, P. (2008). Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: A randomized trial. JAMA, 300(17), 2003-2011.

Yancovitz, S. R., Des Jarlais, D. C., Peyser, N. P., Drew, E., Friedmann, P., Trigg, H. L., & Robinson, J. W. (1991). A randomized trial of an interim methadone maintenance clinic. American Journal of Public Health, 81(9), 1185-1191.

Zanis, D. A., & Woody, G. E. (1998). One-year mortality rates following methadone treatment discharge. Drug and Alcohol Dependence, 52, 257-260.

Zutler, M., & Holty, J. E. (2011). Opioids, sleep, and sleep-disordered breathing. Current Pharmaceutical Design, 17(15), 1443-1449.

Поділіться з Вашими друзьями:
1   ...   70   71   72   73   74   75   76   77   ...   85


Психічні та поведінкові розлади iconПредмет психології
Записати у словник визначення понять: психологія, психіка, психічні процеси, психічні стани, психічні властивості особистості, біхевіоризм,...
Психічні та поведінкові розлади iconЛабораторна робота 3 Дослідження психічних властивостей людини-оператора Мета роботи Вивчити загальні поняття про психічні прцеси які
Вивчити загальні поняття про психічні прцеси які відбуваються у людини-оператора: відчуття, сприйняття, уявлення І уява, увага, пам’ять...
Психічні та поведінкові розлади iconЗгідно поставленої мети були намічені основні задачі дослідження
При цьому клінічна картина протікає важко І прогностично несприятливо, гостра симптоматика часто переходить в хронічну, провокуючи...
Психічні та поведінкові розлади iconРобоча програма навчальної дисципліни сучасні проблеми міжетнічних та міжцивілізаційних взаємин у теоретичному та практичному вимірах
Психічні та поведінкові розлади iconПсихічні й психофізіологічні властивості людини-оператора людина-оператор як ланка
Саме вона формулює мету функціонування системи, планує, спрямовує й контролює основні процеси. Тому діяль-ність оператора є підгрунтям...

База даних захищена авторським правом ©biog.in.ua 2017
звернутися до адміністрації

    Головна сторінка